MetaCap

Biomea Fusion Inc. (BMEA)

NASDAQ: BMEAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.5744-0.014 (-2.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BMEA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$41.75M
EPS (TTM)
-$0.10
52-week range
0.45 – 2.24
Day range
0.5445 – 0.60
Volume / Avg
1.12M / 2.22M
Beta
—

52-week range

$0.45$2.24

BMEA stock today

Biomea Fusion (BMEA) closed at $0.5744 on Nov 20, down 2.38% (-$0.014), versus the S&P 500's 3.70% decline. Shares are 74.3% below their 52-week high of $2.24, set on Apr 20, 2026 and 27.6% above the 52-week low of $0.45, near the bottom of the past year's range. BMEA is down 53.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.5%.

Biomea Fusion has posted a net loss over the last twelve months (EPS of -$0.10), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Biomea Fusion

Company profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Michael J. M. Hitchcock Ph.D.
Headquarters
San Carlos, CA
Employees
37
IPO year
2021

Financial highlights

Full financials

Biomea Fusion reported a net loss of $61.8 million, compared with a loss of $138.4 million a year earlier. Diluted earnings per share came in at -$1.18.

Biomea Fusion annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-61.80M$-138.43M$-117.25M$-81.83M$-41.57M
EPS (diluted)$-1.18$-3.83$-3.44$-2.80$-1.74

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$7.00+1118.66%

  • Strong buy 2
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 1

Target range

Low $4.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.27 vs $-0.18
Surprise
-50.00%

BMEA news

All BMEA news

Biomea Fusion peers

Health Care sector
BMEA peer companies
CompanyPrice% ChgMarket capCompare
MREOMereo BioPharma Group plc ADR0.26-5.45%$41.52Mvs BMEA
OSTXOS Therapies Incorporated0.803-2.12%$42.00Mvs BMEA
INCRIntercure Ltd.3.24-7.69%$42.03Mvs BMEA
ELTXElicio Therapeutics Inc.1.45-3.33%$41.05Mvs BMEA
CRBPCorbus Pharmaceuticals Holdings Inc.2.06-15.40%$42.45Mvs BMEA
TLPHTalphera Inc.0.7852+6.25%$40.80Mvs BMEA
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs BMEA
RLYBRallybio Corporation15.47-0.32%$43.32Mvs BMEA

Indexes, lists and sector

Biomea Fusion stock FAQ

What is Biomea Fusion's stock price today?

BMEA last traded at $0.5744 as of Nov 20, 4:00 PM EST, down 2.38% on the day. Prices are delayed at least 15 minutes.

Who is Biomea Fusion's CEO?

Dr. Michael J. M. Hitchcock Ph.D. is the chief executive officer of Biomea Fusion Inc., which has about 37 employees.

What is the BMEA 52-week high?

The 52-week high for BMEA is $2.24 and the 52-week low is $0.45. The stock is currently 74.3% below its high.

Compare BMEA